Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

The pharmaceutical company has entered into a $600 million financing facility with investment management giant KKR. Bausch said it plans to use the extra funds for general corporate purposes.

Why Shares of Bausch Health Jumped on Friday

Shares of Bausch Health Companies Inc. BHC, -1.03% rallied 2.1% in premarket trading Friday, after the pharmaceutical company announced a $600 million financing facility with KKR & Co. Inc. KKR, -2.46%, an alternative asset management firm. Bausch Health said it plans to use the proceeds from the facility, which provides access to additional liquidity for five years, for general corporate purposes.

Bausch Health's stock rallies after $600 million financing agreement with KKR

Oral Health Care Companies Celebrate the 100th ADHA Conference by Highlighting New Data for the Treatment of Periodontal Disease LAVAL, QC / ACCESSWIRE / July 7, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and its oral health care business, OraPharma, today announced its presence at the American Dental Hygienists' Association (ADHA®) Annual Conference held in Chicago, IL from July 7-9, 2023. ADHA is the largest and oldest organization representing the professional interests of more than 226,000 dental hygienists in the United States.

OraPharma to Participate in the First-Ever Research and Technology Pavilion Sponsored by Pacific Dental Services(R) at the American Dental Hygienists' Association (ADHA(R)) Annual Conference

Bausch + Lomb purchased Blink brands from a J&J subsidiary for $106.5 million to expand its over-the-counter offerings.

Bausch + Lomb Buys Blink Brands to Expand Eye Drop Portfolio

Bausch + Lomb Corporation was spun out of Bausch Health Companies Inc. this year - after years of speculation - and the new entity is an eye disease specialist. The parent company owns nearly 90% of the spun-out company's stock. Bausch + Lomb announced at the end of last month it would acquire Novartis dry eye disease asset XIIDRA and other assets in a deal worth up to $2.5bn.

Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes

Johnson & Johnson

Bausch + Lomb said on Thursday it has acquired Johnson & Johnson's eye and contact lens drops for $106.5 million in an all-cash deal to expand its portfolio of over-the-counter eye care products.

Bausch + Lomb buys J&J's dry eye relief drops for $107 mln

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb today announced the purchase of the Blink® product line of OTC eye and contact lens drops from Johnson & Johnson Vision.

Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops

Novartis

Eye care company Bausch + Lomb said it would pay $1.75 billion to acquire a portfolio of eye care products from Swiss healthcare giant Novartis.

Bausch + Lomb Buys Novartis Drugs for $1.75 Billion Expanding Eye Care Portfolio

Bausch + Lomb Corp has announced plans to buy dry eye disease treatment Xiidra from Swiss pharma giant Novartis AG (ADR) (NYSE:NVS) in a deal that could be valued as high as $2.5 billion. The two companies reached an agreement Friday for a portion of Novartis' eye medicine portfolio, as Novartis shifts its focus towards the development of new and more profitable drugs.

Bausch + Lomb to acquire dry eye treatment from Novartis in potential $2.5B deal

Bausch + Lomb Corp. BLCO, +7.98% confirmed that it was buying the “dry eye” treatment Xiidra from Novartis AG NVS, +0.90% NOVN, +0.72% in a deal valued at $2.5 billion. Under terms of the deal, Bausch + Lomb will make an upfront payment of $1.75 billion in cash, and could make milestone payments of up to $750 million based based on sales and commercialization thresholds.

Bausch + Lomb to buy ‘dry eye' treatment from Novartis in a $2.5 billion deal

Bausch + Lomb Corp

LAVAL, QC / ACCESSWIRE / June 30, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has entered into a definitive agreement with Novartis to acquire XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye. Under the terms of the agreement, Bausch + Lomb, through an affiliate, has agreed to acquire XIIDRA, libvatrep and AcuStream from Novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations up to $750 million based on sales thresholds and pipeline commercialization.

Bausch Health's Bausch + Lomb to Acquire Novartis' XIIDRA(R)

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has entered into a definitive agreement with Novartis under which Bausch + Lomb will acquire XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye. “This acquisition i.

Bausch + Lomb Will Acquire XIIDRA®

Bausch + Lomb Corp said on Friday it would buy Swiss pharma company Novartis' dry-eye drop for $1.75 billion, boosting its drug portfolio for the disease as the market for its treatment grows.

Bausch + Lomb to buy Novartis dry-eye drug for $1.75 billion

Three XIFAXAN® (rifaximin) Research Posters to Be Featured LAVAL, QC / ACCESSWIRE / June 19, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced its presence at the European Association for the Study of the Liver (EASL) Congress 2023. XIFAXAN® (rifaximin) data was selected for inclusion in the Cirrhosis and its complication's session.

Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2023

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of PreserVision® AREDS 2 Formula soft gels plus coenzyme Q10 (CoQ10). Developed as a convenient two-in-one option, PreserVision AREDS 2 Formula eye vitamins plus CoQ10 is the only eye vitamin that combines the exact nutrient formula recommended by the National Eye Institute (NEI.

Bausch + Lomb Launches PreserVision® AREDS 2 Formula Soft Gels Plus CoQ10 in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced that researchers will present the results of 11 scientific poster presentations involving the company's consumer, vision care and pharmaceutical products during the American Optometric Association (AOA) Optometry's Meeting e-posters Virtual Event, which is taking place from June 13-14, 2023. In.

Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting

Bausch (BHC) declines after the FDA grants tentative approval to Norwichs ANDA for a generic version of Xifaxan.

Bausch (BHC) Down on Tentative Approval to Xifaxan ANDA

Markets overreacted to Norwich suing the FDA. Investors must consider recently reported weak Q1 results of Bausch Health. Reasons BHC stock is a buy from here.

What To Do After Bausch Health Stock Plunged By Nearly 9% Again

Today, Bausch Health Company acknowledged the FDA's decision to tentatively approve a generic version of Xifaxan. The company also noted that final approval remains off the table until Oct. 2, 2029.

Why Bausch Health Companies Stock Is Tanking Today

LAVAL, QC / ACCESSWIRE / June 6, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, understand that in a June 2, 2023, letter, the U.S. Food and Drug Administration (FDA) granted Norwich Pharmaceuticals Inc. Tentative Approval of its Abbreviated New Drug Application (ANDA) for XIFAXAN® (rifaximin) 550 mg. At the same time, the FDA confirmed in its Letter that it cannot grant Final Approval until Oct. 2, 2029 - the date specified by the presiding judge in his Final Judgment in Salix Pharmaceuticals, LTD et al.

Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Biotrue® Hydration Boost Contact Lens Rehydrating drops, the first and only preservative-free rehydrating drop in a multi-dose bottle that is indicated to lubricate and rewet soft contact lenses, including daily disposables, and rigid gas permeables. “We're proud to build on.

Bausch + Lomb Launches Biotrue® Hydration Boost Contact Lens Rehydrating Drops in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Bausch + Lomb INFUSE® Multifocal silicone hydrogel (SiHy) daily disposable contact lenses. Featuring a next-generation material infused with ProBalance Technology™ for all-day comfort and the company's unique 3-Zone Progressive™ design, the new lens addresses the dynamic visi.

Bausch + Lomb Launches Bausch + Lomb INFUSE® Multifocal Silicone Hydrogel Contact Lenses in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced a reshaping of its executive leadership team, including the elevation of all business unit heads. Luc Bonnefoy, senior vice president (SVP), Surgical; John Ferris, SVP, Consumer; and Yang Yang, SVP, Vision Care; will join the executive management team of the Company reporting directl.

Bausch + Lomb Announces Key Leadership Changes

Cover Your Bases Campaign Kicks Off Oral Health Month with ARESTIN (minocycline HCI) Patient Ambassador Alex Rodriguez LAVAL, QC , May 31, 2023 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its oral health care business, OraPharma, today announced its collaboration with World Series Champion, Alex Rodriguez, to launch a national awareness campaign about the prevalence and impact of gum disease. The Cover Your Bases campaign includes educational content about the disease and encourages patients to talk to their dentist about comprehensive treatment options.

OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease

Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.

News for Bausch Health Companies Inc Stock (BHC)